A process for preparing a compound of formula

##STR00001##

including oxidizing the triphenylmethane sulfone of formula (V) with a quinone chosen from 1,4-benzoquinone, 1,2-benzoquinone, a di(C.sub.1-C.sub.4)alkyl-1,4-benzoquinone, a di(C.sub.1-C.sub.4)alkyl-1,2-benzoquinone, a mono(C.sub.1-C.sub.4)alkyl-1,4-benzoquinone and a mono(C.sub.1-C.sub.4)alkyl-1,2-benzoquinone. A crystalline form of patent blue, sodium salt, can be achieved.

A process for preparing a compound of formula

##STR00001##

including oxidizing the triphenylmethane sulfone of formula (V) with a quinone chosen from 1,4-benzoquinone, 1,2-benzoquinone, a di(C.sub.1-C.sub.4)alkyl-1,4-benzoquinone, a di(C.sub.1-C.sub.4)alkyl-1,2-benzoquinone, a mono(C.sub.1-C.sub.4)alkyl-1,4-benzoquinone and a mono(C.sub.1-C.sub.4)alkyl-1,2-benzoquinone. A crystalline form of patent blue, sodium salt, can be achieved.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

A compound of the formula, plus devices incorporating this compound, and a method of marking such devices: ##STR00001## wherein: A represents a phenyl group, a naphthyl group, a biphenyl group or two phenyl groups linked by a C.sub.1-C.sub.8 alkyl chain; B.sup.1 and B.sup.2 in each occurrence are independently selected side chains of the structure
—(Y.sup.1).sub.n-L-(Y.sup.2).sub.m—X wherein: Y.sup.1 and Y.sup.2 in each occurrence are independently selected from O, CO.sub.2— and CH.sub.2O, m and n in each occurrence are independently selected from 0 or 1; L in each occurrence is a C.sub.2-C.sub.14 straight chain alkyl group; and X in each occurrence is an independently selected cross linkable group; C is a side chain of the structure —(Z.sup.1).sub.p-M-(Z.sup.2).sub.q-E wherein: Z.sup.1 and Z.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, p and q in each occurrence are independently selected from 0 or 1; M is a C.sub.1-C.sub.14 straight chain alkyl group; and E comprises a charge transport group; D is a side chain of the structure —(W.sup.1).sub.r—N—(W.sup.2).sub.s—F wherein: W.sup.1 and W.sup.2 are independently selected from O, CO.sub.2— and CH.sub.2O, r and s in each occurrence are independently selected from 0 or 1; N is a C.sub.1-C.sub.14 straight chain alkyl group; and F comprises a charge transport group or light emitter group; and wherein the charge transport group E does not contain a fluorene group other than those that form part of a spirobifluorenearylamine motif.

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compoundsdiarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier.

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compoundsdiarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.